AA Treatment of CD8+ T Lymphocytes Leads to Increase in Hydroxymethylcytosine Fraction (5hmC/C) and Enhancement of Its Cytotoxic Activity Against Lymphoma Cells. The gene discussed is CD8A; the disease is lymphoma.